Rebecca Champion

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · The Lancet Oncology · 2022 · 234 citations

Medicine, Hematology, Oncology +14

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos et al. · Blood · 2022 · 38 citations · Full text

Medicine, Oncology, Chemotherapy +7

A phase 2, multicentre, open‐label trial (<scp>ACE‐LY</scp>‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

Paolo Strati, Morton Coleman, Rebecca Champion et al. · British Journal of Haematology · 2022 · 30 citations · Full text

Medicine, Oncology, Pharmacology +13

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study

Swaminathan P. Iyer, Auris Huen, Weiyun Z. Ai et al. · Haematologica · 2023 · 23 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · Blood · 2023 · 15 citations

Medicine, Hematology, Oncology +11